At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-Arm, Open-Label, Phase II Trial of Rituximab Plus Sargramostim for the Treatment of Newly Diagnosed Follicular B-Cell Lymphoma in Adults
In Brief
A Phase 2 clinical trial evaluating Rituximab and Sargramostim (GM-CSF) for Lymphoma. Completed, enrolled 60 participants across 1 site.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving rituximab together with GM-CSF may be an effective treatment for follicular B-cell lymphoma. PURPOSE: This phase II trial is studying the side effects and how well giving rituximab together with GM-CSF works in treating patients with newly diagnosed follicular B-cell lymphoma.
Study Details
Timeline
Interventions
375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.
250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.